SCHEMBL4401717

SCHEMBL4401717

CCOc1cccc(NC(=O)N(CCCN2CCC(C)CC2)Cc2ccc(C(=O)Nc3ccccc3NC(=O)OC(C)(C)C)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.43
MAPT P10636 4/20 0.42
ALDH1A1 P00352 2/20 0.42
SLC2A1 P11166 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
USP2 O75604 1/20 0.41
TAAR1 Q96RJ0 1/20 0.40
UBE2M P61081 4/20 0.40
DCUN1D1 Q96GG9 4/20 0.40
TSHR P16473 1/20 0.40
HDAC1 Q13547 5/20 0.40
HDAC6 Q9UBN7 5/20 0.40
HDAC3 O15379 3/20 0.40
HDAC2 Q92769 3/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC4 P56524 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2478980 0.91 USP2 (0.52) MAPTALDH1A1SMN1; SMN2USP2TSHR
SCHEMBL13646274 0.91 EPHX2 (0.45) MAPTALDH1A1SLC2A1SMN1; SMN2USP2
SCHEMBL3831043 0.90 UBE2M (0.48) KDM1AMAPTALDH1A1SLC2A1SMN1; SMN2
SCHEMBL2478906 0.89 KDM1A (0.45) KDM1AMAPTALDH1A1SLC2A1SMN1; SMN2
SCHEMBL3834156 0.87 KDM1A (0.46) KDM1AMAPTALDH1A1UBE2MDCUN1D1
SCHEMBL3835680 0.86 HDAC1 (0.51) SMN1; SMN2TSHRHDAC1HDAC6HDAC3
SCHEMBL2500433 0.85 KDM1A (0.43) KDM1AHDAC1HDAC6HDAC3HDAC2
SCHEMBL3835037 0.85 KDM4E (0.45) KDM1AALDH1A1SMN1; SMN2UBE2MDCUN1D1
SCHEMBL2501968 0.84 TSHR (0.55) MAPTALDH1A1SMN1; SMN2USP2TSHR
SCHEMBL3832650 0.84 RECQL (0.46) MAPTSMN1; SMN2TAAR1TSHRHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 KDM1A 1117/4885MAPT 1576/4885ALDH1A1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.